UBS Starts Henry Schein (HSIC) at Buy

October 6, 2016 7:45 AM EDT
Get Alerts HSIC Hot Sheet
Price: $152.19 +1.17%

Rating Summary:
    7 Buy, 13 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade HSIC Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

UBS initiates coverage on Henry Schein (NASDAQ: HSIC) with a Buy rating and a price target of $186.00.

Analyst Michael Cherny commented, "We are initiating coverage of Henry Schein with a Buy rating and a $186 price target. HSIC has been a long-term share gainer across all its key markets, with recent supersized growth in its Medical business far outpacing the market. The company has developed a consistent 10-12% EPS growth profile that, due to the typical visibility, has been rewarded with a premium multiple. The company’s 2Q slowdown in Dental growth, in our opinion, appears to be short-term in nature, and a return to more normalized growth (in-line with our survey expectations) should drive shares higher."

For an analyst ratings summary and ratings history on Henry Schein click here. For more ratings news on Henry Schein click here.

Shares of Henry Schein closed at $161.34 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Related Entities

UBS

Add Your Comment